

19th May, 2022

To,
The Manager - Corporate Relationship Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001
Scrip Code: BSE - 524500

To,
The Manager - Corporate Compliance
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051
Scrip Code: NSE - KILITCH

Dear Sir/Madam,

Sub: Submission of acknowledgement received from Securities and Exchange Board of India for the report submitted under regulation 10(7) of SEBI(Substantial Acquisition of Shares and Takeovers) Regulations, 2021


Dear Sir/Madam,

Please find enclosed herewith the acknowledgement received from Securities and Exchange Board of India for the report submitted under regulation 10(7) of SEBI(Substantial Acquisition of Shares and Takeovers) Regulations, 2021 for your record.

We request you to kindly take note of the same and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For **Kilitch Drugs (India) Limited**

Mukund Mehta
Managing Director



Bhavin Mehta

B/2501 25th Floor, Plot No 8pt, T3 Evoq, New Cuffe Parade, Wadala Truck Terminal Road,
Mumbai -400037

16th May, 2022

To,
The Securities and Exchange Board of India
Plot No.C4-A, 'G' Block,
Bandra Kurla Complex,
Bandra(East), Mumbai - 400051



Dear Sir/Madam,

Sub: Submission of the Report under Regulation 10(7) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

With reference to the above captioned subject, please find enclosed herewith the Report to be submitted pursuant to Regulation 10(7) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011, in respect of inter-se transfer executed under Regulation 10(1)(a)(i) and (ii) of said SEBI (Substantial Acquisition of Shares and Takeover) Regulation, 2011, as amended, along with non refundable fees of Rs.1,50,000/-.

Request you kindly take the same on record and acknowledge the receipt.

Thanking You,

Yours' Faithfully,

Bhavin Mehta

Encl:-

1. Disclosures under Regulation 10(7)
2. Annexure A
3. Annexure B
4. Annexure C
5. Annexure D
6. DD of Rs.1,50,000/-

Report to SEBI in respect of any acquisition made in reliance upon exemption provided for in regulation 10(1)(a)(i) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011

1 General Details		
a.	Name, address, telephone no., e-mail of acquirer(s) {In case there are multiple acquirers, provide full contact details of any one acquirer (the correspondent acquirer) with whom SEBI shall correspond.}	Bhavin Mehta Address: B/2501 25 th Floor, Plot No 8pt, T3 Evoq, New Cuffe Parade, Wadala Truck Terminal Road, Mumbai -400037 Tel. No.:- 9820003727 E-mail:- bhavinmehta@kilitch.com
b.	Whether sender is the acquirer (Y/N)	Yes
c.	If not, whether the sender is duly authorized by the acquirer to act on his behalf in this regard (enclose copy of such authorization)	N. A.
d.	Name, address, Tel no. and e-mail of sender, if sender is not the acquirer	N. A.
2 Compliance of Regulation 10(7)		
a.	16 th May, 2022	
b.	Whether report has been submitted to SEBI within 21 working days from the date of the acquisition	Yes
c.	Whether the report is accompanied with fees as required under Regulation 10(7)	Yes
3 Compliance of Regulation 10(5)		
a.	Whether the report has been filed with the Stock Exchanges where the shares of the Company are listed, atleast 4 working days before the date of the proposed acquisition.	Yes
b.	Date of Report	12/04/2022
4 Compliance of Regulation 10(6)		
a.	Whether the report has been filed with the Stock Exchanges where the shares of the Company are listed within 4 working days of the acquisition	Yes
b.	Date of Report	26/04/2022
5 Details of the Target Company		
a.	Name & address of TC	Kilitch Drugs (India) Limited
b.	Name of the Stock Exchange(s) where the shares of the TC are listed	National Stock Exchange of India Limited & BSE Limited
6 Details of the acquisition		
a.	Date of acquisition	22/04/2022
b.	Acquisition price per share (in Rs.)	NIL [Inter Se Transfer by Gift]




	c.	Regulation which would have been triggered off, had the report not been filed under Regulation 10(7) (whether Regulation 3(1), 3(2), 4 or 5)	Regulation 3(1)			
	d.	Shareholding of acquirer/s and PACs individually in TC (in terms of no. & as a percentage of the total share/voting capital of the TC)(*)	Before the acquisition		After the acquisition	
			No: of Shares	% w.r.t total share capital /voting rights of TC	No: of Shares	% w.r.t total share capital /voting rights of TC
		i. Mukund Mehta	20,02,415	12.85	8,90,647	05.72
		ii. Bhavin Mehta	20,02,416	12.85	31,14,184	19.99
		iii. Kilitch Company (Pharma) Limited	66,29,342	42.54	66,29,342	42.54
		Total	1,06,34,173	68.25	1,06,34,173	68.25
	e.	Shareholding of seller/s in TC (in terms of no: & as a percentage of the total share/voting capital of the TC)	Before the acquisition		After the acquisition	
			No: of Shares	% w.r.t total share capital /voting rights of TC	No: of Shares	% w.r.t total share capital /voting rights of TC
		Mukund Mehta	20,02,415	12.85	8,90,647	05.72
		Total	20,02,415	12.85	8,90,647	05.72
7.	Information specific to the exemption category to which the instant acquisition belongs - Regulation 10(1)(a)(i)					
	a	Provide the names of the seller/s	Mukund Mehta			
	b	Specify the relationship between the acquirer/s and the seller/s.	Immediate Relative (Father)			
	c	Confirm whether the acquirer(s) and the seller(s) are ' immediate relatives ' as defined in the Regulation 2(1).	As per Annexure - 'A'			
	d	If shares of the TC are frequently traded, volume-weighted average market price (VWAP) of such shares for a period of sixty trading days preceding the date of issuance of notice regarding the proposed acquisition to the stock exchanges where the TC is listed.	NSE : 197.83 BSE: 199.85			
	e	If shares of the TC are infrequently traded, the price as determined in terms of clause	NA			



	(c) of sub-regulation (2) of regulation 8.	
f	Confirm whether the acquisition price per share is not higher by more than twenty-five percent of the price as calculated in (d) or (e) above as applicable.	As per Annexure -- 'B'
g	Date of issuance of notice regarding the proposed acquisition to the stock exchanges where the TC is listed	12-04-2022
h	Whether the acquirers as well as sellers have complied with the provisions of Chapter V of the Takeover Regulations (corresponding provisions of the repealed Takeover Regulations 1997) (Y/N). If yes, specify applicable regulation/s as well as date on which the requisite disclosures were made along with the copies of the same.	YES As per Annexure - 'C'
i	Declaration by the acquirer that all the conditions specified under regulation 10(1)(a)(i) with respect to exemptions has been duly complied with.	As per Annexure - 'D'

I hereby declare that the information provided in the instant report is true and nothing has been concealed there from.



Bhavin Mehta

Place: Mumbai

Date: 16th May, 2022


Bhavin Mehta

B/2501 25th Floor, Plot No 8pt, T3 Evoq, New Cuffe Parade, Wadala Truck Terminal Road,
Mumbai -400037

**ANNEXURE A TO POINT NO. 7(c) OF FORM UNDER REGULATION 10(7)
[RE: KILITCH DRUGS (INDIA) LIMITED]**

DECLARATION

I, Mr. Bhavin Mehta, do and hereby confirm and declare that the acquirer and the seller/s are 'immediate relatives' as defined in the Regulation 2(l) as mentioned in Point No. 7 (c) of form specified under Regulation 10(7).



Bhavin Mehta
Place: Mumbai
Date: 16th May, 2022


Bhavin Mehta

B/2501 25th Floor, Plot No 8pt, 13 Evoq, New Cuffe Parade, Wadala Truck Terminal Road,
Mumbai -400037

**ANNEXURE B TO POINT NO.7(f) OF FORM UNDER REGULATION 10(7)
[RE: KILITCH DRUGS (INDIA) LIMITED]**

DECLARATION

I, Mr. Bhavin Mehta, do and hereby confirm and declare that, the acquisition price per share is not higher by more than twenty-five percent of the price calculated as per volume-weighted average market price (VWAP) of such shares for a period of sixty trading days preceding the date of issuance of notice regarding the proposed acquisition to the stock exchanges where the Kilitch Drugs (India) Limited (i.e. Target Company) is listed.



Bhavin Mehta
Place: Mumbai
Date: 16th May, 2022

Bhavin Mehta

B/2501 25th Floor, Plot No 8pt, T3 Evoq, New Cuffe Parade, Wadala Truck Terminal Road,
Mumbai -400037


**ANNEXURE C TO POINT NO.7(h) OF FORM UNDER REGULATION 10(7)
[RE: KILITCH DRUGS (INDIA) LIMITED]**

DECLARATION

Based on the information received and documents furnished by Kilitch Drugs (India) Limited (i.e. Target Company) I, Mr. Bhavin Mehta, do and hereby confirm and declare that, the acquirers as well as sellers have complied with the provisions of Chapter V of the SEBI Takeover Regulations.

The details of the compliances made under Chapter V of the Takeover Regulations by the Acquirers and Sellers are as under:-

Sr. No.	Compliance	Name of the Acquirer / Seller	Date
1	Under Regulation 29 (2) of SEBI(Substantial Acquisition of Shares and Takeover) Regulations, 2011	Bhavin Mehta [Acquirer]	22/04/2022
2	Under Regulation 29 (2) of SEBI(Substantial Acquisition of Shares and Takeover) Regulations, 2011	Mukund Mehta [Seller]	22/04/2022



Bhavin Mehta

Place: Mumbai

Date: 16th May, 2022


Bhavin Mehta

B/2501 25th Floor, Plot No 8pt, T3 Evoq, New Cuffe Parade, Wadala Truck Terminal Road,
Mumbai -400037

**ANNEXURE D TO POINT NO.7(i) OF FORM UNDER REGULATION 10(7)
[RE: KILITCH DRUGS (INDIA) LIMITED]**

DECLARATION

I, Mr. Bhavin Mehta, do and hereby confirm and declare that, all the conditions specified under regulation 10(1)(a)(i) with respect to exemptions has been duly complied with.



Bhavin Mehta
Place: Mumbai
Date: 16th May, 2022

A/c Payee



kotak

Kotak Mahindra Bank - Mumbai - Sion

641579

Valid for three months from date of issue

दिनांक	7	0	5	2	0	2	2
Date	D	D	M	M	Y	Y	Y

UTILITY FORMS PVT. LTD./CTS-2010

On demand pay **SECURITIES AND EXCHANGE BOARD OF INDIA**

को चा उनके आदेश पर Or Order

रुपये Rupees **One Lakh Fifty Thousand only**

अदा करें।

₹	1,50,000.00
---	-------------

Payable At *** Not Over INR. 1,50,000.00 ***

For Value Received
for Kotak Mahindra Bank Ltd.

Mumbai



Purchaser:

LILITCH DRUGS INDIA LTD

(Drawee Branch)

NDalvi
Navnath L Dalvi
KMB-53784
Authorizer

Please sign above this line

Chopra 182081
CHOPRA
182081

⑈ 64 1579 ⑈ 0004850001⑈

१६